Daratumumab to help lower rejection risk before heart transplant
Treatments studied
Part of Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial tests daratumumab to reduce your body’s immune reaction (HLA antibodies) before a heart or heart-and-kidney transplant. It may help lower the risk of immediate, severe rejection in people who already have high antibody levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have heart or combined heart-and-kidney transplant listed as your active plan
- Have a high rejection antibody level (cPRA over 50%)
- Blood tests must be in safe ranges: white blood cell type (ANC) > 1,500 and kidney function (creatinine clearance) > 20
- Liver tests must be acceptable: bilirubin < 1.5 times the lab’s upper limit, and AST/ALT less than about 2.5–3 times the upper limit
- No prior daratumumab (anti-CD38) or certain other study drugs/devices within the past month or so
- Must be able to give informed consent and not be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
This trial tests giving a drug called Darzalex Faspro before the usual desensitization and a stem cell transplant for people at high risk of graft failure due to donor-specific antibodies. The goal is to prevent the transplant from failing.
Hear when a new Cardiac Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.